



(11) **EP 1 001 813 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**A61K 47/40** (2006.01) **A61K 31/505** (2006.01)

(86) International application number:  
**PCT/EP1998/003477**

(48) Corrigendum issued on:  
**12.02.2014 Bulletin 2014/07**

(87) International publication number:  
**WO 1998/058677 (30.12.1998 Gazette 1998/52)**

(45) Date of publication and mention  
of the grant of the patent:  
**02.05.2003 Bulletin 2003/18**

(21) Application number: **98930793.9**

(22) Date of filing: **02.06.1998**

(54) **PHARMACEUTICAL FORMULATIONS CONTAINING VORICONAZOLE**

VORICONAZOL-ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN

FORMULATIONS PHARMACEUTIQUES CONTENANT DU VORICONAZOLE

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **21.06.1997 GB 9713149**

(43) Date of publication of application:  
**24.05.2000 Bulletin 2000/21**

(73) Proprietors:  
• **Pfizer Limited**  
**Sandwich, Kent CT13 9NJ (GB)**  
Designated Contracting States:  
**GB**  
• **Pfizer Inc.**  
**New York, NY 10017 (US)**  
Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GR IE IT LI LU NL  
PT SE**

(72) Inventor: **HARDING, Valerie, Denise**  
**Sandwich,**  
**Kent CT13 9NJ (GB)**

(74) Representative: **Hayles, James Richard**  
**Pfizer**  
**ATTENTION: ADDRESS INACTIVE - USE ASS-NR**  
**- CDR (FR)**

(56) References cited:  
**EP-A- 0 357 241 EP-A- 0 440 372**  
**WO-A-91/11172 WO-A-94/02518**  
**WO-A-97/01552**

Remarks:

The file contains technical information submitted after  
the application was filed and not included in this  
specification

**EP 1 001 813 B8**